High Risk of Postpartum Relapses in Neuromyelitis Optica Spectrum Disorder
Authors
Affiliations
Objective: To study the effect of pregnancy on the frequency of neuromyelitis optica spectrum disorder (NMOSD) relapse and evaluate rates of pregnancy-related complications in an international multicenter setting.
Methods: We administered a standardized survey to 217 women with NMOSD from 7 medical centers and reviewed their medical records. We compared the annualized relapse rate (ARR) during a baseline period 2 years prior to a participant's first pregnancy to that during pregnancy and to the 9 months postpartum. We also assessed pregnancy-related complications.
Results: There were 46 informative pregnancies following symptom onset in 31 women with NMOSD. Compared to baseline (0.17), ARR was increased both during pregnancy (0.44; = 0.035) and during the postpartum period (0.69; = 0.009). The highest ARR occurred during the first 3 months postpartum (ARR 1.33). A total of 8 of 76 (10.5%) with onset of NMOSD prior to age 40 experienced their initial symptom during the 3 months postpartum, 2.9 times higher than expected.
Conclusions: The postpartum period is a particularly high-risk time for initial presentation of NMOSD. In contrast to published observations in multiple sclerosis, in neuromyelitis optica, relapse rate during pregnancy was also increased, although to a lesser extent than after delivery.
Budtarad N, Ongphichetmehta T, Siritho S Sci Rep. 2025; 15(1):4011.
PMID: 39893222 PMC: 11787356. DOI: 10.1038/s41598-025-88624-x.
Pregnancy characteristics in Egyptian female patients with NMOSD.
Gad A, Kishk N, Shalaby N, Heikal E, Fouad A, Merghany N Mult Scler J Exp Transl Clin. 2024; 10(3):20552173241271878.
PMID: 39139781 PMC: 11320409. DOI: 10.1177/20552173241271878.
Hu Y, Zou F, Lu W Neurol Sci. 2024; 45(9):4471-4479.
PMID: 38565746 DOI: 10.1007/s10072-024-07501-z.
Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.
Nakashima S, Hao A, Uchio N, Matsumoto H Cureus. 2024; 16(2):e55010.
PMID: 38550492 PMC: 10973794. DOI: 10.7759/cureus.55010.
Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions.
Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R Ann Clin Transl Neurol. 2023; 10(11):2053-2064.
PMID: 37675826 PMC: 10647007. DOI: 10.1002/acn3.51893.